jens juul holst glp-1 Researcher receives prize for huge contribution to modern treatment of diabetes and obesity Professor Jens Juul Holst on

For many people, non-GLP-1 medications, alone or in combination, can produce meaningful, sustainable results when chosen thoughtfully

Here is the quick reference: That is the short answer

Medication eligibility and outcomes depend on individual clinical evaluation

Table of Contents Understanding Ozempic's Half-Life and Duration in the Body Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus

Contraindications Because no GLP-1 patches have been approved, there are no official contraindications for this form

Wegovy [package insert]